1. Home
  2. PRAX vs UVSP Comparison

PRAX vs UVSP Comparison

Compare PRAX & UVSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • UVSP
  • Stock Information
  • Founded
  • PRAX 2015
  • UVSP 1876
  • Country
  • PRAX United States
  • UVSP United States
  • Employees
  • PRAX N/A
  • UVSP N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • UVSP Major Banks
  • Sector
  • PRAX Health Care
  • UVSP Finance
  • Exchange
  • PRAX Nasdaq
  • UVSP Nasdaq
  • Market Cap
  • PRAX 950.8M
  • UVSP 822.1M
  • IPO Year
  • PRAX 2020
  • UVSP 1989
  • Fundamental
  • Price
  • PRAX $47.08
  • UVSP $29.82
  • Analyst Decision
  • PRAX Strong Buy
  • UVSP Hold
  • Analyst Count
  • PRAX 10
  • UVSP 2
  • Target Price
  • PRAX $102.00
  • UVSP $29.00
  • AVG Volume (30 Days)
  • PRAX 578.2K
  • UVSP 109.2K
  • Earning Date
  • PRAX 08-04-2025
  • UVSP 07-23-2025
  • Dividend Yield
  • PRAX N/A
  • UVSP 2.95%
  • EPS Growth
  • PRAX N/A
  • UVSP 12.33
  • EPS
  • PRAX N/A
  • UVSP 2.73
  • Revenue
  • PRAX $7,765,000.00
  • UVSP $298,354,000.00
  • Revenue This Year
  • PRAX N/A
  • UVSP $11.76
  • Revenue Next Year
  • PRAX $3,567.38
  • UVSP $4.25
  • P/E Ratio
  • PRAX N/A
  • UVSP $10.93
  • Revenue Growth
  • PRAX 338.45
  • UVSP 4.09
  • 52 Week Low
  • PRAX $26.70
  • UVSP $22.83
  • 52 Week High
  • PRAX $91.83
  • UVSP $32.86
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 42.83
  • UVSP 49.90
  • Support Level
  • PRAX $44.25
  • UVSP $28.14
  • Resistance Level
  • PRAX $49.97
  • UVSP $30.64
  • Average True Range (ATR)
  • PRAX 3.36
  • UVSP 0.77
  • MACD
  • PRAX -0.89
  • UVSP 0.17
  • Stochastic Oscillator
  • PRAX 18.84
  • UVSP 69.71

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About UVSP Univest Financial Corporation

Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.

Share on Social Networks: